Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

Many cancer types metastasize to bone. This propensity may be a product of genetic traits of
the primary tumour in some cancers. Upon arrival, cancer cells establish interactions with …

Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell
transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with …

Background The emergence of highly active novel agents has led some to question the role
of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent …

B-cell maturation antigen (BCMA), a member of the tumor necrosis factor family of receptors,
is predominantly expressed on the surface of terminally differentiated B cells. BCMA is …

Importance Recently, the benefit of adding daratumumab to the proteasome inhibitor–based,
3-drug combination of bortezomib, lenalidomide, and dexamethasone for patients with …

Detecting persistent minimal residual disease (MRD) allows the identification of patients with
an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after …

Abstract Treatment options in multiple myeloma (MM) are increasing with the introduction of
complex multi-novel-agent-based regimens investigated in randomized clinical trials …

Few prospective studies have examined posttransplant chimeric antigen receptor (CAR) T
cell infusion as candidates for front‐line consolidation therapy for high‐risk multiple …

Overcoming multidrug resistance represents a major challenge for cancer treatment. In the
search for new chemotherapeutics to treat malignant diseases, drug repurposing gained a …